Takeda Pharmaceutical Co. has agreed to pay more than $2.3 billion to settle lawsuits accusing the company of hiding its Actos diabetes medicine’s cancer risks, according to a Bloomberg article. Takeda directors still must vote on the deal, which should resolve more than 8,000 suits, said unnamed sources who asked not to be identified.
The deal would offer a payment of more than $287,000 per case to those who sign up for the settlement program, the story said, while former Actos users whose injuries warrant more compensation can continue to litigate their claims, sources said.
Read the full story
